<DOC>
	<DOCNO>NCT01081691</DOCNO>
	<brief_summary>The purpose study assess safety tolerability CNTO 5825 follow single intravenous ( IV ) subcutaneous ( SC ) dose administration healthy volunteer .</brief_summary>
	<brief_title>A Study Evaluating Intravenous Subcutaneous Administration Human Monoclonal Antibody ( CNTO 5825 ) Healthy Volunteers</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , placebo control , double-blind ( neither physician subject know name assign study medication ) study assess safety , tolerability , immune response , pharmacokinetics ( body drug ) , pharmacodynamics ( drug body ) CNTO 5825 . The study population consist 48 healthy volunteer 16 healthy atopic volunteer . Five dose level study agent assess . Participants require stay research center study agent administration inpatient portion study return out-patient visit . Safety assessment perform throughout study include obtain evaluate laboratory test , vital sign ( e.g. , blood pressure ) , occurrence severity adverse event . Placebo ( contain inactive substance ) one five dose level CNTO 5825 give . Healthy volunteer give single IV infusion ( directly vein ) single dose 3 injection skin . Healthy atopic volunteer give one dose IV infusion . There screen period 4 week . All participant study 17 week dose administration .</detailed_description>
	<criteria>Healthy man woman clinically significant abnormality Body weight range 50 100 kg inclusive Body mass index ( BMI ) 18.5 30 kg/m2 inclusive For healthy atopic patient : history atopic allergy Known suspect intolerance hypersensitivity biologic medication component formulation use study Received experimental antibody biologic therapy within previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>CNTO 5825</keyword>
	<keyword>Safety</keyword>
	<keyword>Phase I</keyword>
	<keyword>Healthy adult</keyword>
	<keyword>Healthy Atopic adult</keyword>
</DOC>